Etsuko Moriyama
Overview
Explore the profile of Etsuko Moriyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moriyama E, Shimose S, Niizeki T, Iwamoto H, Tanaka M, Shirono T, et al.
Curr Oncol
. 2024 Oct;
31(10):5821-5831.
PMID: 39451736
This retrospective study aimed to evaluate the impact of atezolizumab plus bevacizumab-transcatheter arterial chemoembolization (TACE) sequential therapy in unresectable hepatocellular carcinoma (HCC), especially in patients with intermediate-stage HCC. A total...
2.
Sakai M, Iwamoto H, Shimose S, Niizeki T, Nakano M, Shirono T, et al.
Oncology
. 2024 Sep;
:1-12.
PMID: 39265538
Introduction: Atezolizumab (ATZ) and bevacizumab (BEV) combination therapy is widely used in patients with unresectable hepatocellular carcinoma (HCC). However, combination therapy is typically interrupted or discontinued owing to BEV-related adverse...
3.
Suzuki H, Sakai M, Iwamoto H, Shimose S, Niizeki T, Nakano M, et al.
Gastro Hep Adv
. 2024 Aug;
3(4):506-509.
PMID: 39131724
No abstract available.
4.
Shimose S, Iwamoto H, Niizeki T, Tanaka M, Shirono T, Moriyama E, et al.
Int J Mol Sci
. 2023 Sep;
24(18).
PMID: 37762018
This study aimed to evaluate the effect of lenvatinib (LEN) combined with transcatheter intra-arterial therapy (TIT) for advanced-stage hepatocellular carcinoma (HCC) after propensity score matching (PSM). This retrospective study enrolled...
5.
Case Report: A case of complete response to entrectinib in fusion gene-positive parotid gland cancer
Moriyama E, Nagasu S, Tanaka T, Shimotsuura Y, Ono T, Umeno H, et al.
Front Oncol
. 2023 Aug;
13:1247435.
PMID: 37601665
Introduction: Expression of the gene is rare in solid tumors but is highly prevalent in salivary gland secretory carcinomas. Here, we report a case of a complete response to entrectinib...
6.
Shigyo H, Suzuki H, Tanaka T, Moriyama E, Shimotsuura Y, Nagasu S, et al.
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190192
Bevacizumab (BEV) requires an adequate withdrawal period to avoid BEV-related complications during major surgery. However, the safety of BEV administration immediately after surgical placement of the central venous (CV) port,...
7.
Shimose S, Iwamoto H, Shirono T, Tanaka M, Niizeki T, Kajiwara M, et al.
Cancer Med
. 2023 Apr;
12(11):12325-12335.
PMID: 37062077
Background And Aims: We aimed to validate the predictive factors for tumor response and the prognostic impact of conversion therapy aimed at cancer- and drug-free states in patients with unresectable...
8.
Shimose S, Sugimoto R, Hiraoka A, Tanaka M, Iwamoto H, Tanaka Y, et al.
Hepatol Res
. 2022 Nov;
53(2):116-126.
PMID: 36316794
Aim: Few studies have reported the efficacy and safety of ramucirumab (RAM) after atezolizumab plus bevacizumab (Atezo/Beva) treatment and the overall associated outcomes. Thus, we aimed to evaluate the therapeutic...
9.
Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Tani J, Kuzuya T, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230795
Background: Systemic treatments are recommended for advanced hepatocellular carcinoma (HCC) in preserved liver function. However, their effects are unsatisfactory in some tumor conditions, particularly macrovascular invasion (MVI) including major portal...
10.
Shimose S, Hiraoka A, Tanaka M, Iwamoto H, Tanaka T, Noguchi K, et al.
Sci Rep
. 2022 Oct;
12(1):17018.
PMID: 36220865
This study aimed to investigate the clinical characteristics of patients with unresectable hepatocellular carcinoma (HCC), who were eligible for sequential systemic therapy. We evaluated 365 patients with HCC who underwent...